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OBJECTIVE — The Diabetes Care Protocol combines task delegation (a practice nurse),
computerized decision support, and feedback every 3 months. We studied the effect of the
Diabetes Care Protocol on A1C and cardiovascular risk factors in type 2 diabetic patients in
primary care.
RESEARCH DESIGN AND METHODS — In a cluster randomized trial, mean changes
in cardiovascular risk factors between the intervention and control groups after 1 year were
calculated by generalized linear models.
RESULTS — Throughout the Netherlands, 26 intervention practices included 1,699 patients
and 29 control practices 1,692 patients. The difference in A1C change was not signiﬁcant,
whereas total cholesterol, LDL cholesterol, and blood pressure improved signiﬁcantly more in
the intervention group. The 10-year coronary heart disease risk estimate of the UK Prospective
Diabetes Study improved 1.4% more in the intervention group.
CONCLUSIONS — Delegation of routine diabetes care to a practice nurse combined with
computerized decision support and feedback did not improve A1C but reduced cardiovascular
risk in type 2 diabetes patients.
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I
mproving patients’ outcomes, in order
to reduce cardiovascular risk, remains
one of the most important goals in di-
abetescare.Structuredandregularreview
ofpatientshasbeenshowntoimprovethe
process of care (1), and team changes and
casemanagementhavebeenshowntoim-
proveglycemiccontrol(2).Computerized
decision support systems (CDSSs) have
been shown to improve practitioners’ per-
formance(3),andfeedbackonperformance
giventoprimarycarephysicians(PCPs)has
been demonstrated by Ziemer et al. (4) to
lower patients’ A1C levels and improve
practitioners’ behavior.
Against this background, the Diabe-
tes Care Protocol (DCP) was developed,
which reduced patients’ cardiovascular
risk in a before-after study (5). The cur-
rent randomized clinical trial aims to in-
vestigate the effects of the DCP on A1C
and cardiovascular risk in type 2 diabetic
patients in primary care.
RESEARCH DESIGN AND
METHODS— Primary care practices
throughout the Netherlands that were
not involved in other diabetes care im-
provement programs were block ran-
domized to intervention (26 practices)
or the control group (29 practices). The
number of PCPs working in each prac-
tice and the presence of a practice nurse
before intervention were taken into ac-
count before randomization. The inter-
vention, also described elsewhere (5),
consisted of 1) diabetes consultation
hour run by a practice nurse, 2) a CDSS
that contained a diagnostic and treat-
mentalgorithmbasedontheDutchtype
2 diabetes guidelines (6) and provided
patient-speciﬁc treatment advice, 3)a
recall system, and 4) feedback every 3
months regarding the percentage of pa-
tients meeting the treatment targets
(cessation of smoking, A1C 7%, sys-
tolic blood pressure 140 mmHg, total
cholesterol 4.5 mmol/l, LDL choles-
terol 2.5 mmol/l, and BMI 27 kg/
m
2) on both the practice and the patient
levels (6). The PCPs were advised that
they should prescribe new medication
and refer patients if necessary. The con-
trol group continued with the same di-
abetes care that they had received
before entering the study, which means
that diabetes care was provided by the
PCP or by a practice nurse under PCP
responsibility. The University Medical
Center Utrecht ethics committee ap-
provedthestudy,andpatientsprovided
written consent.
From the 171,821 registered pa-
tients, all type 2 diabetic patients were
identiﬁed. Patients who had a short life
expectancy, were unable to visit the pri-
marycarepractice,orwerereceivingdi-
abetes treatment from a medical
specialist were excluded. Initially,
3,979 patients were eligible (2,136 in
the control group and 1,843 in the in-
tervention group), but 548 subjects re-
fused to participate (409 control and
139 intervention subjects), and an ad-
ditional 40 (35 control and 5 interven-
tion subjects) failed to participate for
unknown reasons (for both groups, P 
0.05). The ﬁnal, mainly Caucasian,
study population consisted of 3,391 pa-
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vention). After 1 year, 2,841 patients
(1,389 control and 1,452 intervention)
completed a follow-up examination;
187 patients (115 control and 72 inter-
vention) refused to participate in the ﬁ-
nal measurements, and 13 others (12
control and 1 intervention) failed to
show for unknown reasons (for both
groups, P  0.05). The groups did not
differ with regard to the number of pa-
tients who died, moved, became termi-
nally ill, or were referred to a specialist.
Between March 2005 and August
2007, patients were each seen twice for
annual diabetes checkups. Patients who
did not show received one reminder. In
the CDSS, age, sex, ethnicity, duration of
diabetes, and smoking habits were regis-
tered. A1C, total cholesterol, and HDL
cholesterol were measured in local labo-
ratories. LDL cholesterol was calculated.
Blood pressure was measured according
to a standard operating procedure.
The 10-year coronary heart disease
(CHD)riskestimate,asestablishedbythe
UK Prospective Diabetes Study (UKPDS)
(7), was calculated using the above-
mentioned variables, excluding LDL
cholesterol.
The primary outcome was the
1-year difference in A1C. Secondary
outcomes were the 1-year difference in
the 10-year UKPDS CHD risk estimate
and the percentage of patients that
reached A1C 7%, systolic blood pres-
sure 140 mmHg, total cholesterol
4.5 mmol/l, and LDL cholesterol
2.5 mmol/l (6).
We performed intention-to-treat
analyses with baseline values carried for-
wardinthecaseofmissingvalues.Tocor-
rect for clustering at the practice level,
generalized linear models were used, and
after clustering had been taken into ac-
count,a0.3%differenceinA1Canda2%
difference in UKPDS CHD risk could be
detected with 90% power (0.05),
with at least 1,080 patients in each treat-
ment arm.
RESULTS— There were more solo
practices (58 vs. 50%) and fewer duo
practices(24vs.30%)comparedwithna-
tional data (8). The mean  SD age
(46.8  7.4 years) of the participating
PCPs was comparable with the mean
Dutch PCP age (8). Baseline characteris-
ticsoftheinterventionandcontrolgroups
werecomparable,exceptforsmokingsta-
tus, history of cardiovascular disease, and
HDL cholesterol levels (Table 1).
The difference in A1C change be-
tween the two groups was not signiﬁcant.
Systolic and diastolic blood pressure and
total and LDL cholesterol improved sig-
niﬁcantlymoreintheinterventiongroup.
Asaresult,thecalculated10-yearUKPDS
CHD risk decreased 1.4% more in the in-
tervention group. After 1 year, signiﬁ-
cantly more patients in the intervention
group reached the treatment targets, with
18.9%ofthepatientsmetingalltreatment
targets (Table 1).
CONCLUSIONS — The DCP is the
ﬁrst pragmatic diabetes care interven-
tion using a CDSS that improves patient
outcome. As recommended by the Na-
tional Institute of Clinical Excellence,
we calculated the 10-year UKPDS CHD
risk estimate for all subjects and used
this measurement as a determinant of
clinical care. Recently, the Action in Di-
Table 1—Baseline parameters, 1-year differences of clinical outcome parameters and process parameters within and between groups (N 
3391)
Intervention group






between groups* Baseline After 1 year Baseline After 1 year
Baseline characteristics
Age (years) 65.2  11.3 65.0  11.0
Sex (% male) 48.2 49.8
Race/ethnicity (% Caucasian) 97.7 97.6
Duration of diabetes (years) 5.8  5.7 5.4  5.8
History of cardiovascular disease 47.1 63.3
Current smoking 22.6 20.7 16.6 15.5 1.1† 0.7–1.7
Clinical outcome
A1C (%) 7.1  1.3 6.9  1.1 7.0  1.1 6.9  1.0 0.07 0.02 to 0.16
Systolic blood pressure (mmHg) 149  22 143  20 149  21 147  20.8 3.3‡ 0.5–6.0
Diastolic blood pressure (mmHg) 83  11 80  11 82  11 82  10.6 2.2‡ 1.0–3.5
Total cholesterol (mmol/l) 5.0  1.0 4.6  0.9 4.9  1.1 4.8  1.1 0.2‡ 0.1–0.3
HDL cholesterol (mmol/l) 1.36  0.36 1.37  0.37 1.32  0.35 1.33  0.36 0.007 0.038 to 0.023
LDL cholesterol (mmol/l) 2.8  0.92 2.5  0.88 2.8  0.95 2.6  0.97 0.15‡ 0.07–0.23
10-year UKPDS CHD risk (%)§ 22.5  16.5 20.6  15.0 21.7  15.8 21.6  15.6 1.4‡ 0.3–2.6
Process of care
A1C 7% 60.8 68.0 61.6 64.2 1.4†‡ 1.0–1.8
Systolic blood pressure 140
mmHg 41.0 53.9 39.5 42.2 1.7†‡ 1.2–2.2
Total cholesterol 4.5 mmol/l 36.2 49.0 38.5 45.3 1.3†‡ 1.0–1.6
LDL cholesterol 2.5 mmol/l 41.1 53.5 43.8 49.8 1.3†‡ 1.0–2.8
All treatment targets 10.3 18.9 10.9 13.4 1.6†‡ 1.3–2.1
DataaremeansSDorpercentunlessotherwiseindicated.*Generalizedlinearmodel.†OR.‡P0.05forbetween-groupcomparison.§The10-yearUKPDSCHD
risk (%) was calculated using date of diabetes onset (age  duration of diabetes), sex, ethnicity, smoking, A1C, systolic blood pressure, total cholesterol, and HDL
cholesterol.
Diabetes Care Protocol improves cardiovascular risk
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VANCE) study showed that A1C
reduction does not prevent CHD (9).
This result indicates that we should fo-
cus on the patient’s total cardiovascular
risk proﬁle. Our study showed no dif-
ference in A1C change between the two
treatment arms, but the DCP led to im-
proveddiabetescare,whichisshownby
a 1.4% higher reduction in 10-year
CHD risk estimate in the intervention
group.
The DCP combines several interven-
tions. The CDSS structures diabetes care,
which may lead to improvements in the
process of care (1). In addition, the DCP
addedapracticenursewhoactedasacase
managerandprovidedperiodicfeedback.
Both interventions can improve blood
glucose control (2,4).
Practices were self-selected, which
may suggest a special interest of the PCP
in improving diabetes care. This could be
the reason why baseline values of A1C,
blood pressure, and cholesterol were
lower than those of most other Dutch
primary care diabetes studies (10).
Because mean A1C at baseline was almost
at the treatment target, there was little
roomforimprovement.Changesinblood
pressure and cholesterol, however, were
signiﬁcant.
The percentage of patients who
reached all treatment targets remained
strikingly low: 18.9%. This could be ex-
plained by overly strict targets (11), phy-
sicians inert in prescribing more
medications (4), or noncompliant pa-
tients (12). Whether the effects of the
DCP will sustain has to be determined by
longer-term follow-up data.
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